Voting for the ASCO Election is now open. All eligible members are encouraged to cast their ballots: brnw.ch/21wXgpl

In this short video, Dr. @jrgralow.bsky.social shares why finding the best dose of drug for each patient is important. Watch now and learn how you can get involved: tinyurl.com/6e36vvkh

Fun and energizing talk last week at the International Student House of DC. My talk: Beyond Borders: A Career in Global Oncology. The Power of Partnerships, Advocacy, and Collaboration. @ascocancer.bsky.social

Key Takeaways from Dr. DeMichele #ASCO25

Every day during #ASCO25, Dr. John Sweetenham will offer concise expert analysis on some of the day's top abstracts on the #ASCODailyNews Podcast. Listen to today's episode on Day 1 and check back daily at 4:30pm CT for more: dailynews.ascopubs.org/do/podcast-d... #oncsky

Workplace Burnout Among Oncologists Has Risen: What Can Be Done? Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

Burnout among oncology and healthcare professionals is on the rise, but what can be done? The Cancer Network spoke with Dr. Eric Winer on ways to address burnout and improve well-being, incl findings published in our Journal of Clinical Oncology.

ASCO Education: The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new...

So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!

@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/H...

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer www.thebreastonline.com/article/S096...

Nice piece in @cancertherapyadv.bsky.social about managing cancer care in the setting of natural disasters. @ascocancer.bsky.social

Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025

Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025

In science, we expand our knowledge & change our thinking through peer-reviewed, evidence based publications—it is what separates science from, well, political power grabs evidently trying to stop science.
#FundScience #PublishScience #ShareScience

.@ascocancer.bsky.social engages in judicial and legislative advocacy to protect NIH funding: www.asco.org/news-initiat...

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies!
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it

The OncoAlert🚨 Network along with our partners
invite you to the #OncoAlertColloquium

REGISTER for FREE HERE👉 https://buff.ly/3CChgre
February 3-9, 2025 💯% Virtual& Interactive

Watch Our #BreastCancer Faculty @hoperugo.bsky.social 🇺🇸
Presenting on Advanced TNBC Year in Review

🎉 MedNews Week Turns 3! 🎉

Earlier this month, MedNews Week celebrated its 3rd anniversary! 🥳 We are deeply grateful to our incredible Keynote Speakers for supporting our mission to advance global medical education and combat misinformation. 🌍📚

Negative Screening Results and Colorectal Cancer This cohort study compares the long-term risk of colorectal cancer incidence and mortality among individuals receiving a negative colonoscopy screening result with those not undergoing endoscopy.

Interesting new study looking at screening colonoscopy intervals and individual's risk profiles - >10 years may be optimal with lower risk
jamanetwork.com/journals/jam...

OUR COMPLETE #SABCS24 🚨Newsletter IS OUT

REGISTER at oncoalert360.com OR buff.ly/48Xpgz0

This Includes all of OUR TOP pick of TRIALS presented during these last 4 days in San Antonio & Video Interviews from our Collaborators at @vjoncology.bsky.social and high5md

📣 ASCO is now here 🦋!
@ascocancer.bsky.social
@ascopost.bsky.social

#OncSky #AcademicSky #MedSky #Oncology #CancerResearch

@oncoalert.bsky.social
@oncodaily.bsky.social
@onclive.bsky.social

The OncoAlert 🚨Newsletter NOW OUT Covering September November 28-Dec 5, 2024

REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0

✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more

Good info here from CA: A Cancer Journal for Clinicians. Content is free, year round!
Happy holidays as we buckle in for a tumultuous few years.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.

SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.

www.nature.com/articles/s41...

Thanks @tmprowell.bsky.social
Will take this off social and send to our fellows. Such a great opportunity. it cannot live in the sky alone.

Trends in breast cancer–specific death by clinical stage at diagnoses between 2000 and 2017 AbstractBackground. Approximately 40 000 individuals die from metastatic breast cancer each year. We examined what fractions of annual breast cancer–specif

Now in JNCI “Pts w stage 1 & 2 breast cancer have excellent prognosis, yet account for >60% breast cancer–specific death due to large #. To ⬇️ breast cancer death, strategies neededed to identify,treat pts w/early stage BC w/ risk for recurrence” @oncoalert.bsky.social

doi.org/10.1093/jnci...

Vote in the ASCO Election - now through December 3

Help ASCO choose the Society’s future leaders, plus earn a point toward FASCO designation for voting!

society.asco.org/about-asco/a...

The ASCO25 abstract submitter:

Thanks for posting! A favorite activity is the recordings I do with Sara Tolaney around new data at our international meetings! @oncoalert.bsky.social @ucsfcancer.bsky.social

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer A video from Sara Tolaney, posted on Nov 19, 2024.

📣JUST IN: Dr. Sara Tolaney @danafarber.bsky.social BreastOnc & Dr. Hope Rugo @hoperugo.bsky.social UCSFCancer share insights on Top #SABCS24 abstracts! Watch
📽️ on 👇
tinyurl.com/SABCS24eBC

#bcsm #oncsky #medsky #breastcancer

Disease-Specific Hashtags for Online Communication About Cancer Care This study highlights the usefulness of agreement on disease-specific hashtags for effective online communication about cancer care.

Since #oncsky is forming here just wanted to post about the origins of the healthcare hashtags, all of which used "sm" to anchor = social media
jamanetwork.com/journals/jam... 1/3